A Multicenter Randomized Double-Blind Placebo-Controlled Induction Study of the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease @ Long Island Clinical Research Associates

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

Conditions:
Crohn's Disease

Age: Between 18 - 80 Years

Gender: Male or Female

Other Inclusion Criteria:

Male or female aged >=18 to <= 80 years, or minimum age of adult consent according to local regulations, at the Baseline Visit.Diagnosis of CD for at least 3 months prior to Baseline

Demonstrated intolerance or inadequate response to conventional or to biologic therapy for CD

You may not be eligible for this study if the following are true:

Subject with a current diagnosis of ulcerative colitis or indeterminate colitis

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.